NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Creative Medical Technology Holdings, Inc. (CELZ) Stock Analysis

Creative Medical Technology Holdings, Inc. (CELZ) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

CELZ

$0.74

−$0.01 (−1.63%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CELZ with… →

CELZ Key Statistics

As of Oct 21, 2026
Trading
Open
$0.75
Previous Close
$0.75
Day's Range
0.74–0.76
52-Week Range
0.62–6.25
Volume
50.74K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.91
Valuation
Market Cap
$6.23M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2,075.05
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.07
Financials (FY)
Revenue (FY)
$6.00K−45.45%
Net Income (FY)
−$6.00M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
7.59M
1-Year Return
−79.99%
Dividend and dates
Avg Volume
6.76M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, CELZ closed at $0.74, −79.99% over 1 year.

Creative Medical Technology Holdings, Inc. (CELZ) has a market capitalization of $6.23M.

In fiscal 2025, CELZ reported revenue of $6.00K.

CELZ Stock Return by Calendar Year

Creative Medical Technology Holdings, Inc. (CELZ) 10-year return: what $10,000 became

1 year
$10,000 $2,001
−79.99%
5 years
$10,000 $93
−99.07%
10 years
$10,000 $0.02
−99.9998%

If you had invested $10,000 in Creative Medical Technology Holdings, Inc. (CELZ) 10 years ago, at the close on October 21, 2016, it would have been worth $0.02 at the close on October 21, 2026: −99.9998% in total, −73.16% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−62.12%
2025−15.15%
2024−49.89%
2023+20.97%
2022−82.76%
2021−84.10%
2020−38.22%
2019−96.97%
2018−26.67%
2017−97.35%
2016 (partial year)+0.00%

As of October 21, 2026.

CELZ Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$6.00K−$6.00M−99,916.8%
2024$11.00K−$5.49M−49,940.7%
2023$9.00K−$5.29M−58,739.7%
2022$88.60K−$10.14M−11,449.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$6.00K$3.81K−$6.14M−$6.00M−99,916.8%
2024$11.00K$6.60K−$5.74M−$5.49M−49,940.7%
2023$9.00K$5.40K−$5.62M−$5.29M−58,739.7%
2022$88.60K$60.11K−$10.24M−$10.14M−11,449.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 8 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Creative Medical Technology Holdings, Inc. (CELZ) carries a market capitalisation of $6.23M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 4.

The 52-week range on file runs from $0.62 to $6.25. CELZ last closed at $0.74 on October 21, 2026. That is −$0.01 (−1.63%) against the previous close. The latest close sits 19.74% above that 52-week low.

Financial Health

In fiscal 2025, Creative Medical Technology Holdings, Inc. reported revenue of $6.00K. Against the prior fiscal year total of $11.00K, that is a change of −45.45%. The same year closed with a net loss of $6.00M. Earnings per share on a trailing basis come to −2.07.

Across the 4 fiscal years on file, revenue moves from $88.60K in 2022 to $6.00K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 2,075.05. On price-to-sales that is 156 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

The trailing one-year total return is −79.99%. Across 10 years the annualized return works out at −73.16%. The reported beta is 1.91. Annualized volatility over the trailing 10 years is 308.34%.

Growth & Income

No dividend is on file for CELZ.

2026 is still running; the total return is −62.12% year to date. The strongest complete calendar year on file is 2023 at +20.97%; the weakest is 2017 at −97.35%. Of the 9 complete calendar years on file, 1 finished higher.

Peer Comparison

Creative Medical Technology Holdings, Inc. (CELZ) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Creative Medical Technology Holdings, Inc. CELZ $6.23M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Creative Medical Technology Holdings, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Creative Medical Technology Holdings, Inc.

Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT), a allogenic human perinatal tissue derived cell program, ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, which is phase 2, for the treatment of type 1 diabetes; AlloStemSpine (CELZ 201 ADAPT), which is phase 2, for the treatment of chronic lower back pain; Alova, a platform to treat infertility as a result of premature ovarian failure; StemSpine, a regenerative stem cell procedure to treat degenerative disc disease; OvaStem, a stem cell therapy for premature ovarian failure; CaverStem for erectile dysfunction treatment; and FemCelz for female sexual function treatment. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

Visit website →